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Editor’s key points
† Anaesthetic-induced
developmental
neurotoxicity correlates
with changes in GABAergic
neurotransmission
determined by KCC2
expression.
† The effects of three
general anaesthetics
on KCC2 expression
were determined in
neonatal rats.
† Expression of KCC2 was
not altered, and is
unlikely to contribute to
the neurodevelopmental
effects of anaesthesia.
Background. The developmental transition from depolarizing to hyperpolarizing
g-aminobutyric acid-mediated neurotransmission is primarily mediated by an increase
in the amount of the potassium-chloride cotransporter KCC2 during early postnatal
life. However, it is not known whether early neuronal activity plays a modulatory role
in the expression of total KCC2 mRNA and protein in the immature brain. As general
anaesthetics are powerful modulators of neuronal activity, the purpose of this study
was to explore how these drugs affect KCC2 expression during the brain growth spurt.
Methods. Wistar rat pups were exposed to either a single dose or 6 h of midazolam,
propofol, or ketamine anaesthesia at postnatal days 0, 5, 10, or 15. KCC2 expression
was assessed using immunoblotting, immunohistochemistry, or quantitative
polymerase chain reaction analysis up to 3 days post-exposure in the medial
prefrontal cortex.
Results. There was a progressive and steep increase in the expression of KCC2 between
birth and 2 weeks of age. Exposure to midazolam, propofol, or ketamine up to 6 h at any
investigated stages of the brain growth spurt did not influence the expression of this
cotransporter protein.
Conclusion. I.V. general anaesthetics do not seem to influence developmental
expression of KCC2 during the brain growth spurt.
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Ionic plasticity is a fundamental and unique feature of
g-aminobutyric acid (GABA)-mediated signalling via the
ionotropic GABAA receptor.
1 This implies that, depending
primarily on the transmembrane chloride (Cl2) electro-
chemical gradient, exposure to GABA can induce either
hyperpolarization or depolarization of postsynaptic neu-
rones. In the adult brain, because of low intracellular
Cl2 concentrations, activation of GABAA receptors results
in Cl2 influx and a related membrane hyperpolarization. In
contrast, as intracellular Cl2 concentrations are higher in im-
mature neurones, GABA has a depolarizing and sometimes
even excitatory action during development, including the
initial phases of the brain growth spurt.2 3 The functional
transition of GABAA receptor-mediated neurotransmission
from depolarizing to hyperpolarizing is linked to the devel-
opmental upregulation of the potassium-chloride cotran-
sporter KCC2, a neurone-specific plasmalemmal ion
transporter that mediates K+-gradient fuelled electrically
neutral Cl2 extrusion from cells.1 4 KCC2 expression
increases during the 2nd postnatal week in the rodent cere-
bral cortex,1 5 6 and from the 30th gestational week in
humans.7 8
Despite the physiological importance of the KCC2-
mediated ontogenetic EGABA shift, our knowledge about the
molecular mechanisms underlying progressive upregulation
of this cation-chloride cotransporter during the brain
growth spurt remains elusive. An intriguing and influential
hypothesis suggested that presynaptically released GABA
acts as a self-limiting trophic factor in a negative feedback
loop where depolarizing postsynaptic GABAA receptor
responses and consequent Ca2+ transients are required for
the developmental upregulation of KCC2.9 However, subse-
quent studies showed that developmental KCC2 upregulation
takes place in hippocampal and midbrain cultures in the
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complete absence of GABAA receptor signalling.
10 11 During
embryonic development in mice lacking, the vesicular inhibi-
tory amino acid transporter (Viaat), KCC2 mRNA and protein
levels were unaffected, despite the absence of GABAergic
synaptic transmission.12 Finally, experiments on NKCC1
knock-out mice which lack depolarizing GABAergic signalling
showed no alteration in the expression of KCC2.13 14 There
are also data indicating that growth factor signalling via tyro-
sine kinase receptors (Trk) modulates KCC2 levels. Overex-
pression of brain-derived neurotrophic factor (BDNF) during
embryonic development increases KCC2 mRNA levels in the
mouse forebrain,15 but whether this is a specific effect or
reflects a general acceleration of neuronal maturation is
not known. On the other hand, interictal-like neuronal activ-
ity patterns down-regulate KCC2 via the BDNF-TrkB pathway
in hippocampal slice cultures, and a similar phenomenon has
also been observed in both in vivo and in vitro animal models
of epilepsy.16–18
General anaesthetics are powerful modulators of GABAer-
gic and glutamatergic neurotransmission, and thus of neur-
onal activity.19 Importantly, these drugs also influence
BDNF-TrkB signalling pathways.20–22 An appealing hypoth-
esis is that KCC2 expression could be significantly influenced
by general anaesthetics. This would imply that anaesthesia
exposure during the brain growth spurt would result in an
early non-physiological increase in neuronal KCC2 levels.
This, in turn, might entrain a premature EGABA shift in devel-
oping neuronal networks. Given the fundamental and clinical
importance of this issue, the present work was designed
to study this possibility. By focusing on well-defined time
points during the brain growth spurt, we systematically eval-
uated the effects of midazolam, propofol and ketamine an-
aesthesia on KCC2 expression in the rat medial prefrontal
cortex (mPFC) up to 72 h after drug administration.
Methods
The experimental protocol was conducted according to the
guidelines of the Swiss Federal Veterinary Office and was
approved by the Cantonal Veterinary Office, Geneva, Switzer-
land. Animals were group-housed and bred in the animal
facilities of the University of Geneva Medical School under
light- (12 h light/dark cycle) and temperature-controlled
(20–248C) conditions. Food and water were available at
libitum. Every effort was made to minimize the number of
animals used and their suffering. 0- to 15-day-old Wistar
rats (males and females) were used for all experiments.
Anaesthesia procedures
According to the experimental protocol, general anaesthesia
was induced by intraperitoneal (i.p.) injection of either mida-
zolam (25 mg kg21), propofol (40 mg kg21) or ketamine (30
mg kg21) on postnatal day (PND) 0, 5, 10, or 15. Depending
on the developmental stage, these drugs induced sedation
(i.e. loss of the righting reflex) for 45 and 60 min. In the 6
h-long anaesthesia groups, after these aforementioned
initial dosing regimens, animals then received an hourly i.p.
injection (four in total) of midazolam (12.5 mg kg21), propo-
fol (20 mg kg21), or ketamine (15 mg kg21). Control sham-
treated animals received i.p. injections of physiological
saline at equivalent volumes and frequency in each experi-
mental protocol. All pups underwent the same maternal sep-
aration and handling as anaesthetized animals, and were
kept in individual cages for the duration of the experimental
procedure. Body temperature was monitored and maintained
at 37–388C by means of a heating pad (Harvard Apparatus,
Holliston, MA, USA). In experiments where pups were eutha-
nized at 24 or 72 h after drug exposure, they were replaced
beside their respective mother once fully recovered from
anaesthesia.
Immunohistochemistry
Animals were euthanized by an overdose of pentobarbital
(120 mg kg21 i.p.) and perfused transcardially with ice cold
4% paraformaldehyde (pH 7.4) solution. Brains were then
removed and postfixed for 4 h in 4% paraformaldehyde. Of
note, 40 mm-thick coronal sections of the left hemisphere
were then cut on a vibratome in ice-cold phosphate-based
saline solution (PBS, pH 7.4). For immunolabelling of KCC2,
coronal sections were incubated with rabbit anti-KCC2 anti-
body (Millipore, Billerica, MA, USA; 1:2000 dilution) for 24 h
at ambient temperature in PBS containing sucrose (5%),
bovine serum albumin (2%), Triton X-100 (1%), and sodium
azide (0.1%). Slices were then rinsed in PBS solution and
incubated for an additional 24 h with an Alexa-conjugated
secondary antibody (Molecular Probes, Carlsbad, CA, USA
1:1000). Slices were mounted and coverslipped using Immu-
nomount (Thermo Scientific, Pittsburgh, PA, USA).
Immunoblotting
After decapitation, the prefrontal cortex was rapidly micro-
dissected on ice and subsequently frozen in liquid nitrogen.
Protein extraction from samples was carried out in RIPA
buffer (100 mM Tris-Cl; 300 mM NaCl pH: 7.4, 10% NP-40,
10% sodium deoxycholate) together with a protease inhibi-
tor cocktail (Complete mini, Roche, Basel, Switzerland).
After homogenization with a syringe and sonication, lysates
were centrifugated at 10 000 g for 20 min at 48C, superna-
tants were collected and protein quantified using the Brad-
ford method (Protein Assay, Biorad, Hercules, CA, USA).
Soluble proteins were then denatured for 5 min at 958C
with sodium dodecyl sulphate and b-mercaptoethanol. De-
pending on the developmental stage, 10–30 mg of protein
were equally loaded on a 7.5% polyacrylamide gel. After 90
min of migration at 120 V, proteins were transferred to a
nitrocellulose membrane at 40 V for 1 h. Subsequent to blot-
ting, the membrane was incubated with Ponceau stain to
ensure proper blotting and an equal quantity of protein
loaded. After washing the Ponceau stain, the membrane
was blocked with phosphate buffered saline with tween
(PBST)-5% milk for 1 h in room temperature, then it was
incubated overnight at 48C in a rabbit polycolonal IgG
against KCC2 (Millipore, 1:10 000 dilution). Membranes were
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subsequently washed and incubated with a secondary anti-
body (polyclonal goat anti-rabbit immunoglobulins/HRP,
DakoCytomation, Denmark, 1:2000 dilution), exposed to
luminol reagent (Roche Diagnostics) for 4 min and exposed
to a photographic film (Amersham Hyperfilm ECL, Bucking-
hamshire, UK). Membranes were then treated with a strip-
ping buffer (Restore Western Blot, Thermo Scientific) for 1 h
at room temperature, blocked with PBST-5% milk for 1 h
and incubated with anti b-tubulin antibody (purified anti-
mouse b-tubulin, Covance, Princeton, NJ, USA) for 1 h fol-
lowed by a secondary antibody (polyclonal rabbit anti-mouse
immunoglobulin/HRP, DakoCytomation, Denmark, 1:2000 di-
lution) for 30 min. Protein intensities were quantified using
NIH Image J (Bethesda, MD, USA) and KCC2 expression was
normalized to b-tubulin.
Real-time quantitative polymerase chain reaction
Total RNA of each sample was extracted by RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. RNA quality was verified by Agilent 2100 Bioanaly-
zer (Agilent Technologies, Basel, Switzerland). The following
primer sequences were used for KCC2: forward
5′-GATGCACCTCAC CAAGAA C-3′, reverse 5′-CTGGCTTCTCCTCG
TTGT-3′. 0.5 mg RNA were converted to cDNA using TAKARA
reverse transcription. Than 2-fold dilution series were sub-
jected to SYBR Green PCR assays using triplicates. Relative
gene expression was calculated as described by geNorm,
and average quantities were normalized to three control
(housekeeping) genes for each sample as previously
described.23
Statistics
All mean values are given with the standard error of mean
(SEM). Normality was tested for each distribution (D’Agostino
and Pearson test), and a was set to 5% for all tests. Two-
tailed Student’s test were used for testing statistical signifi-
cance (P,0.05) between groups using Prism software,
Version 5.0a (GraphPad software, Inc., La Jolla, CA, USA).
Results
We first explored the developmental time course of KCC2 ex-
pression in the rat mPFC during the first two weeks of post-
natal life. There was a progressive increase of KCC2
immunoreactivity during this period (Fig. 1A). These observa-
tions were extended by immunoblot analysis of KCC2 levels
in extracts from the mPFC at distinct developmental time
points (Fig. 1B and C). These experiments revealed only very
faint amounts of KCC2 at PND 0, and the expression levels
increased approximately 4-fold by PND 5 [391 (114)% of
PND 0]. A steep, .10-fold increase in the amount of KCC2
was then observed between PND 5 and 10 [3950 (1560)%
of PND 0], and this was followed by a further 3-fold increment
between PND 10 and 15 [14 800 (2680)% of PND 0]. These
results, in line with previous work,24 thus demonstrate a
large increase in the expression of KCC2 during the early
postnatal period in the rat mPFC.
To examine whether and how general anaesthesia-
induced manipulation of neuronal activity and synaptic
transmission affects developmental expression of KCC2 in
the mPFC during the early postnatal period, newborn rats
were exposed to either a single shot or a 6 h anaesthesia
protocol at PND 0, 5, 10, and 15 using midazolam, propofol,
or ketamine. The effects of these treatments on KCC2
levels were then assessed by immunoblot (midazolam and
ketamine) or quantitative polymerase chain reaction (qPCR)
analysis (propofol) 6, 24, and 72 h after drug exposure. The
most extensive analysis on KCC2 expression was carried
out using midazolam as this drug is not only considered as
a prototype of GABAA receptor potentiating drugs, but is
also widely used in other fields of medicine. Exposing
animals at PND 0 to a single dose of midazolam (25 mg
kg21 i.p.) induced loss of the righting reflex for 45 min.
Analyses of KCC2 levels 6 h after drug exposure revealed
a large interindividual heterogeneity in responses to this
treatment (Fig. 2A). At this stage, when only scarce
amounts of KCC2 can be detected in the cerebral cortex,
midazolam-induced changes in KCC2 expression varied
between 50 and 585% compared with the mean of control
values, a variability that was several fold higher compared
with the variability between control saline-treated animals
(values ranging between 50 and 202% of the mean of
control). The magnitude of the apparent variability after mid-
azolam administration was somewhat decreased at later
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Fig 1 Developmental expression of KCC2 in the rat medial pre-
frontal cortex during the early postnatal period. (A) Immunohis-
tochemistry reveals a progressive increase in the amount of
KCC2 between PND 0 and 15. (B) Representative immunoblots
of samples from medial prefrontal cortex tissue demonstrating
the developmental increase in KCC2 expression. (C) Quantitative
analyses of immunoblotting. Six animals from three independent
litters were used. KCC2 levels are normalized to those of
b-tubulin and results are expressed as mean (SEM) on a logarith-
mic scale. PND, postnatal day. Scale bar in (A): 400 mm.
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post-exposure time points but remained larger than in
control groups (Fig. 2B and C). Importantly, statistical analysis
revealed no significant differences between control and
single dose midazolam-treated groups either at 6 h
(P¼0.13), 24 h (P¼0.54), or 72 h (P¼0.33) after drug injec-
tion. When midazolam anaesthesia was maintained for 6 h
at PND 0, many animals displayed respiratory depression
after a few hours and some died. Given these observations
together with the technical difficulties to perform reliable ar-
terial blood sampling in this age group in order to determine
adequacy of blood gas values, we thus decided to omit the
6 h protocol at this age. In contrast, as previously demon-
strated, we could safely deliver a 6 h anaesthetic at later de-
velopmental stages.25 26 As seen in Figures 3–5, the range of
interindividual variability after midazolam exposure was
comparable with interindividual variability between controls,
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Fig 2 Effect of a single dose midazolam exposure at postnatal day 0 on KCC2 protein levels at 6 h (A), 24 h (B), and 72 h (C) after drug admin-
istration. Upper left panels describe the experimental protocol; lower left panels show representative immunoblots; right panels display the
quantitative analysis of the related immunoblots. At each time point, at least seven animals from three independent litters were used for
quantitative analysis. Each single dot represents KCC2 levels from one animal. Results were normalized to the internal control b-tubulin
and are expressed as mean (SEM). After verification for normal distribution (D’Agostino and Pearson omnibus normality test), statistical signifi-
cance between control and drug exposed groups were checked using the two-tailed Student’s t-test. PND, postnatal day; C, control (saline
injected) animals; M, midazolam injected animals; ns, non-significant difference between groups.
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Fig 3 Effect of midazolam exposure at postnatal day 5 on KCC2
protein levels. (A) Experimental protocols. From (B–D) Quantitative
analyses of immunoblots after single dose (left panels) or 6 h
(right panels) midazolam exposure at 6 h (B), 24 h (C), and 72 h
(D) after drug administration. At each time point, at least seven
animals from three independent litters were used for quantita-
tive analysis. Each single dot represents KCC2 levels from one
animal. Results were normalized to the internal control
b-tubulin and are expressed as mean (SEM). After verification for
normal distribution (D’Agostino and Pearson omnibus normality
test), statistical significance between control and drug exposed
groups was checked using the two-tailed Student’s t-test. PND,
postnatal day; C, control (saline injected) animals; M, midazolam
injected animals; ns, non-significant difference between groups.
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Fig 4 Effect of midazolam exposure at postnatal day 10 on KCC2
protein levels. (A) Experimental protocols. From (B–D) Quantitative
analyses of immunoblots after single dose (left panels) or 6 h
(right panels) midazolam exposure at 6 h (B), 24 h (C), and 72 h
(D) after drug administration. At each time point, at least seven
animals from three independent litters were used for quantita-
tive analysis. Each single dot represents KCC2 levels from one
animal. Results were normalized to the internal control
b-tubulin and are expressed as mean (SEM). After verification for
normal distribution (D’Agostino and Pearson omnibus normality
test), statistical significance between control and drug exposed
groups was checked using the two-tailed Student’s t-test. PND,
postnatal day; C, control (saline injected) animals; M, midazolam
injected animals; ns, non-significant difference between groups.
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and neither single dose nor 6 h midazolam-based anaesthe-
sia protocols revealed significant alterations in KCC2 levels up
to 3 days after exposure at PND 5, 10, or 15. Altogether, these
findings indicate that exposure up to 6 h to the GABAA recep-
tor potentiator midazolam does not induce significant
changes in KCC2 expression patterns during the postnatal
period during which KCC2 levels reach near-adult values.4
To evaluate if other general anaesthetics exert comparable
effects on KCC2 expression as midazolam, we next focused
on propofol and investigated the impact of this drug on
KCC2 expression at the mRNA level using quantitative PCR.
In line with data obtained using midazolam, these experi-
ments revealed no effect of either a single or a 6 h propofol
exposure on KCC2 mRNA levels at PND 5, 10, and 15 when
tested 6 h post-exposure (Fig. 6). Finally, we investigated
how anaesthetics-induced blockade of NMDA receptors using
ketamine affects KCC2 levels. As seen in Figure 7, up to a
6 h exposure to ketamine at any developmental stage
tested did not affect KCC2 expression. Altogether, these find-
ings demonstrate that anaesthesia-induced modulation of
neuronal activity and neurotransmission per se did not influ-
ence developmental expression levels of KCC2 during the
brain growth spurt.
Discussion
In agreement with previous observations,1 we found an im-
portant developmental increase in the amount of the
cation-chloride cotransporter KCC2 in the rat medial pre-
frontal cortex during the first 2 weeks of postnatal life. Expos-
ure to midazolam, propofol, or ketamine for up to 6 h at any
investigated stages of the brain growth spurt, however, did
not influence the expression of this cotransporter either at
the mRNA or at the protein level. These in vivo results thus
indicate that general anaesthetic-induced potentiation of
GABAA receptors or blockade of NMDA receptors does not
induce KCC2 expression. They also suggest that transient
alterations in neural activity do not modulate the level of
expression of this cotransporter during early postnatal devel-
opment in rat.
In addition to driving functional connectivity in the
adult brain, neurotransmitters also play a fundamental role
during the development of the central nervous system.27
Amongst them, GABA is of particular relevance as this neuro-
transmitter and its receptors are present from early stages
of development, and have been implicated in progenitor
proliferation and cell migration.28–30 Importantly, GABAA
receptor-mediated membrane depolarization is considered
to be a key regulator during early stages of both excitatory
and inhibitory synaptogenesis in developing neurones.30–32
Ectopic expression of KCC2 in immature neurones induces
a premature shift of GABAergic responses from excitation
to inhibition.33–35 Interestingly, this genetic manipulation
increases the expression of functional GABAergic synapses
in cultured hippocampal neurones and in the Xenopus
tadpole visual system.31 33 We have recently demonstrated
that premature expression of KCC2 in pyramidal neurones
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Fig 5 Impact of midazolam exposure at postnatal day 15 on
KCC2 protein levels. (A) Experimental protocols. (B–D) Quantitative
analyses of immunoblots after single dose (left panels) or 6 h
(right panels) midazolam exposure at 6 h (B), 24 h (C), and 72 h
(D) after drug administration. At each time point, at least seven
animals from three independent litters were used for quantita-
tive analysis. Each single dot represents KCC2 levels from one
animal. Results were normalized to the internal control
b-tubulin and are expressed as mean (SEM). After verification for
normal distribution (D’Agostino and Pearson omnibus normality
test), statistical significance between control and drug exposed
groups was checked using the two-tailed Student’s t-test. PND,
postnatal day; C, control (saline injected) animals; M, midazolam
injected animals; ns, non-significant difference between groups.
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of the cerebral cortex leads to increased dendritic spino-
genesis and a related increase in spontaneous excitatory
activity of these cells, an effect that was not related to
the ion transporter function of KCC2.36 37 Altogether,
these experimental findings suggest that events leading
to pathophysiological alterations of KCC2 levels would
have fundamental impact on the functions of developing
neuronal circuitries. In line with this possibility, recent
clinical observations suggest that alterations in KCC2 ex-
pression might contribute to schizophrenia and to the
development of affective disorders.38 39
The hypothesis that GABAA-acting general anaesthetics
might impair the expression of KCC2 during development
was motivated by several lines of previous experimental
work (see Introduction). Interestingly, propofol-induced
impairment of long-term potentiation in hippocampal slice
cultures has been shown to be correlated with sustained ex-
pression of KCC2.40 We have recently demonstrated that both
general anaesthetics and ectopic expression of KCC2 induce
increased dendritic spinogenesis in the cerebral cortex.25 37
41 42 These latter observations raised the intriguing possibility
that general anaesthetic-induced dendritic spinogenesis is
mediated by KCC2, most probably through the involvement
of GABAergic and neurotrophic signalling pathways.
However, our present results, showing no effect of midazo-
lam, propofol, and ketamine on KCC2 expression at any
stage of the brain growth spurt, clearly demonstrate that
this is not the case. Our results are in line with previous
observations which were mainly done in cultures,10–14 and
give further arguments suggesting that neither ionotropic
glutamatergic nor GABAergic neurotransmission is required
for the postnatal developmental expression of KCC2. It
should, however, be pointed out that while physiological
neuronal activity which is attenuated or abolished by anaes-
thetics does obviously not influence the rates of KCC2 tran-
scription and translation, pathophysiological activity leads
to down-regulation of KCC2 transcription in mature neu-
rones16–18 and to trafficking of KCC2 protein to the mem-
brane in immature neurones.43 It is also important to note
that in our study we evaluated only three currently used
i.v. anaesthetics. Thus, further studies would be necessary
to determine whether volatile anaesthetics exert similar
effects. This issue could be of potential relevance especially
in light of data suggesting increased seizure activity after
sevoflurane exposure in neonatal brain.44 Also, as in clinical
practice it is more common to use a combination of anaes-
thetics, it will be necessary to elucidate the impact of such
paradigms on KCC2 expression. Finally, as our study
focused on the medial prefrontal cortex, we cannot exclude
that anaesthetics might modulate KCC2 expression in other
brain regions.
In conclusion, i.v. general anaesthetics do not influence the
postnatal expression of KCC2 during the brain growth spurt.
Most importantly as general anaesthetics are powerful modu-
lators of neuronal activity, our work also suggests that KCC2
gene expression is not influenced in cortical neurones in an
activity-dependent manner during normal development.
Declaration of interest
None declared.
Funding
This work was founded by the Swiss National Science Foun-
dation (grant 31003A-130625 to L.V.) and by the Academy
of Finland and the Letten Foundation (to K.K.).
References
1 Blaesse P, Airaksinen MS, Rivera C, Kaila K. Cation-chloride cotran-
sporters and neuronal function. Neuron 2009; 61: 820–38
2 Ben-Ari Y, Cherubini E, Corradetti R, Gaiarsa JL. Giant synaptic
potentials in immature rat CA3 hippocampal neurones. J Physiol
1989; 416: 303–25
3 Sipila ST, Huttu K, Soltesz I, Voipio J, Kaila K. Depolarizing GABA
acts on intrinsically bursting pyramidal neurons to drive giant de-
polarizing potentials in the immature hippocampus. J Neurosci
2005; 25: 5280–89
4 Rivera C, Voipio J, Payne JA, et al. The K+/Cl2 co-transporter KCC2
renders GABA hyperpolarizing during neuronal maturation.
Nature 1999; 397: 251–55
5 Wang C, Shimizu-Okabe C, Watanabe K, et al. Developmental
changes in KCC1, KCC2, and NKCC1 mRNA expressions in the
rat brain. Brain Res Dev Brain Res 2002; 139: 59–66
6 Stein V, Hermans-Borgmeyer I, Jentsch TJ, Hubner CA. Expression
of the KCl cotransporter KCC2 parallels neuronal maturation and
the emergence of low intracellular chloride. J Comp Neurol 2004;
468: 57–64
7 Vanhatalo S, Palva JM, Andersson S, Rivera C, Voipio J, Kaila K.
Slow endogenous activity transients and developmental expres-
sion of K+-Cl2 cotransporter 2 in the immature human cortex.
Eur J Neurosci 2005; 22: 2799–804
8 Hyde TM, Lipska BK, Ali T, et al. Expression of GABA signaling
molecules KCC2, NKCC1, and GAD1 in cortical development and
schizophrenia. J Neurosci 2011; 31: 11088–95
9 Ganguly K, Schinder AF, Wong ST, Poo M. GABA itself promotes the
developmental switch of neuronal GABAergic responses from
excitation to inhibition. Cell 2001; 105: 521–32
10 Ludwig A, Li H, Saarma M, Kaila K, Rivera C. Developmental
up-regulation of KCC2 in the absence of GABAergic and glutama-
tergic transmission. Eur J Neurosci 2003; 18: 3199–206
11 Titz S, Hans M, Kelsch W, Lewen A, Swandulla D, Misgeld U. Hyper-
polarizing inhibition develops without trophic support by GABA in
cultured rat midbrain neurons. J Physiol 2003; 550: 719–30
12 Wojcik SM, Katsurabayashi S, Guillemin I, et al. A shared vesicular
carrier allows synaptic corelease of GABA and glycine. Neuron
2006; 50: 575–87
13 Pfeffer CK, Stein V, Keating DJ, et al. NKCC1-dependent
GABAergic excitation drives synaptic network maturation during
early hippocampal development. J Neurosci 2009; 29: 3419–30
14 Sipila ST, Huttu K, Yamada J, et al. Compensatory enhancement
of intrinsic spiking upon NKCC1 disruption in neonatal hippocam-
pus. J Neurosci 2009; 29: 6982–88
15 Aguado F, Carmona MA, Pozas E, et al. BDNF regulates spontan-
eous correlated activity at early developmental stages by increas-
ing synaptogenesis and expression of the K+/Cl2 co-transporter
KCC2. Development 2003; 130: 1267–80
16 Rivera C, Li H, Thomas-Crusells J, et al. BDNF-induced TrkB activa-
tion down-regulates the K+-Cl2 cotransporter KCC2 and impairs
neuronal Cl2 extrusion. J Cell Biol 2002; 159: 747–52
KCC2 and anaesthesia BJA
i17
17 Rivera C, Voipio J, Thomas-Crusells J, et al. Mechanism of activity-
dependent downregulation of the neuron-specific K-Cl cotran-
sporter KCC2. J Neurosci 2004; 24: 4683–91
18 Jin X, Huguenard JR, Prince DA. Impaired Cl- extrusion in layer V
pyramidal neurons of chronically injured epileptogenic neocortex.
J Neurophysiol 2005; 93: 2117–26
19 Rudolph U, Antkowiak B. Molecular and neuronal substrates for
general anaesthetics. Nat Rev Neurosci 2004; 5: 709–20
20 Popic J, Pesic V, Milanovic D, et al. Propofol-induced changes in
neurotrophic signaling in the developing nervous system in
vivo. PLoS One 2012; 7: e34396
21 Ponten E, Fredriksson A, Gordh T, Eriksson P, Viberg H.
Neonatal exposure to propofol affects BDNF but not CaMKII,
GAP-43, synaptophysin and tau in the neonatal brain
and causes an altered behavioural response to diazepam
in the adult mouse brain. Behav Brain Res 2011; 223: 75–80
22 Lu LX, Yon JH, Carter LB, Jevtovic-Todorovic V. General anesthesia
activates BDNF-dependent neuroapoptosis in the developing rat
brain. Apoptosis 2006; 11: 1603–15
23 Vandesompele J, De Preter K, Pattyn F, et al. Accurate normaliza-
tion of real-time quantitative RT-PCR data by geometric aver-
aging of multiple internal control genes. Genome Biol 2002; 3:
1–12
24 Payne JA, Rivera C, Voipio J, Kaila K. Cation-chloride
co-transporters in neuronal communication, development and
trauma. Trends Neurosci 2003; 26: 199–206
25 Briner A, Nikonenko I, De Roo M, Dayer A, Muller D, Vutskits L.
Developmental stage-dependent persistent impact of propofol
anesthesia on dendritic spines in the rat medial prefrontal
cortex. Anesthesiology 2011; 115: 282–93
26 Jevtovic-Todorovic V, Hartman RE, Izumi Y, et al. Early exposure to
common anesthetic agents causes widespread neurodegenera-
tion in the developing rat brain and persistent learning deficits.
J Neurosci 2003; 23: 876–82
27 Owens DF, Kriegstein AR. Developmental neurotransmitters?
Neuron 2002; 36: 989–91
28 LoTurco JJ, Owens DF, Heath MJ, Davis MB, Kriegstein AR. GABA
and glutamate depolarize cortical progenitor cells and inhibit
DNA synthesis. Neuron 1995; 15: 1287–98
29 Behar TN, Li YX, Tran HT, et al. GABA stimulates chemotaxis
and chemokinesis of embryonic cortical neurons via calcium-
dependent mechanisms. J Neurosci 1996; 16: 1808–18
30 Wang DD, Kriegstein AR. Defining the role of GABA in cortical
development. J Physiol 2009; 587: 1873–79
31 Akerman CJ, Cline HT. Depolarizing GABAergic conductances
regulate the balance of excitation to inhibition in the developing
retinotectal circuit in vivo. J Neurosci 2006; 26: 5117–30
32 Akerman CJ, Cline HT. Refining the roles of GABAergic
signaling during neural circuit formation. Trends Neurosci 2007;
30: 382–89
33 Chudotvorova I, Ivanov A, Rama S, et al. Early expression of KCC2
in rat hippocampal cultures augments expression of functional
GABA synapses. J Physiol 2005; 566: 671–79
34 Fiumelli H, Cancedda L, Poo MM. Modulation of GABAergic trans-
mission by activity via postsynaptic Ca2+-dependent regulation of
KCC2 function. Neuron 2005; 48: 773–86
35 Lee H, Chen CX, Liu YJ, Aizenman E, Kandler K. KCC2
expression in immature rat cortical neurons is sufficient to
switch the polarity of GABA responses. Eur J Neurosci 2005; 21:
2593–99
36 Li H, Khirug S, Cai C, et al. KCC2 interacts with the dendritic cyto-
skeleton to promote spine development. Neuron 2007; 56:
1019–33
37 Fiumelli H, Briner A, Puskarjov M, et al. An ion
transport-independent role for the cation-chloride cotransporter
KCC2 in dendritic spinogenesis in vivo. Cereb Cortex 2013; 23:
378–88
38 Kalkman HO. Alterations in the expression of neuronal chloride
transporters may contribute to schizophrenia. Prog Neuropsycho-
pharmacol Biol Psychiatry 2011; 35: 410–14
39 Tao R, Li C, Newburn EN, et al. Transcript-specific associations of
SLC12A5 (KCC2) in human prefrontal cortex with development,
schizophrenia, and affective disorders. J Neurosci 2012; 32:
5216–22
40 Wang W, Wang H, Gong N, Xu TL. Changes of K+ -Cl2 cotranspor-
ter 2 (KCC2) and circuit activity in propofol-induced impairment
of long-term potentiation in rat hippocampal slices. Brain Res
Bull 2006; 70: 444–49
41 De Roo M, Klauser P, Briner A, et al. Anesthetics rapidly promote
synaptogenesis during a critical period of brain development.
PLoS One 2009; 4: e7043
42 Briner A, De Roo M, Dayer A, Muller D, Habre W, Vutskits L. Volatile
anesthetics rapidly increase dendritic spine density in the rat
medial prefrontal cortex during synaptogenesis. Anesthesiology
2010; 112: 546–56
43 Khirug S, Ahmad F, Puskarjov M, Afzalov R, Kaila K, Blaesse P. A
single seizure episode leads to rapid functional activation of
KCC2 in the neonatal rat hippocampus. J Neurosci 2010; 30:
12028–35
44 Constant I, Seeman R, Murat I. Sevoflurane and epileptiform EEG
changes. Paediatr Anaesth 2005; 15: 266–74
Handling editor: H. C. Hemmings
BJA Lacoh et al.
i18
